Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AMAZON.COM, INC.

(AMZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amazon com : Cloud-powered diagnostic tools are critical to fighting COVID-19

04/12/2021 | 08:37am EDT
AWS to distribute $12 million in 2021 and expand scope of its initiative to fight COVID-19.

2020 was a year like no other. By March, the COVID-19 virus had spread around the world, impacting families, businesses, and communities. Many are still fighting the spread of the virus, which has introduced several new variants that are threatening our communities. The speed at which the virus spread left COVID-19 diagnostics lagging and the healthcare community looking for new ways to use technology to help.

As countries grappled with the challenge of scaling COVID-19 testing, we launched the Amazon Web Services (AWS) Diagnostic Development Initiativeto help organizations around the world apply the power of the cloud to accelerate diagnostics research and development. Through this initiative, AWS committed $20 million in computing credits and customized expertise from the AWS Professional Services team to support customers using AWS to drive diagnostic innovations.

In the first phase of the initiative, AWS helped 87 organizations in 17 countries ranging from nonprofits and research institutions to startups and large businesses. We have awarded $8 million supporting a range of diagnostic projects, including molecular tests for antibodies, antigens, and nucleic acids; diagnostic imaging; wearables; and data analytics tools that use artificial intelligence and machine learning to detect the virus.

Chest X-Ray images from the AIforCOVID project of COVID-19 patients shows how the project used technology to extract a large number of quantitative features from chest x-rays to train the machine learning models to predict prognosis of COVID-19 patients.
Chest X-Ray images from the AIforCOVID project of COVID-19 patients. Panels A and B show patients with severe outcome, although the radiological visual inspection may suggest severe and mild prognoses, respectively. Panels C and D show images of patients with mild outcome, although the radiological visual inspection may suggest severe and mild prognosis, respectively.
Chest X-Ray image from the AIforCOVID project of a COVID-19 patient, shows the difference between manual segmentation of the affected area (green) versus technology-enabled segmentation (red).

As we launch the next phase, we are excited to broaden the AWS Diagnostic Development Initiative's scope and distribute the remaining $12 million this year. Starting April 12, we are expanding the scope to three new areas: 1) early disease detection to identify outbreaks at the individual and at the community level; 2) prognosis to better understand disease trajectory; and 3) public health genomics to bolster viral genome sequencing worldwide.

AWS will prioritize COVID-19 projects but will also evaluate projects focused on other infectious diseases. We will accept applications through the end of the year, with priority consideration given to applications received before July 31. Interested organizations can apply here.

'We have seen transformative innovations in how we diagnose disease over the past year, from machine learning-powered X-ray imagery analysis to new developments in rapid, high quality, and direct-to-consumer tests,' said Dr. Vin Gupta, chief medical officer of Amazon's COVID-19 Response. 'These changes will continue to evolve and improve our ability to respond to future outbreaks. We have already seen inspirational results from the Diagnostic Development Initiative, and we look forward to supporting broader uses of cloud technologies to enable organizations and communities to identify and respond even faster to future outbreaks.'

As the pandemic worsened, we were able to build on a foundation of AWS technology that enabled us to help thousands of communities-millions of lives-all across the United States.
Jim Chou, vice president of engineering at Helix
Speeding customer innovation

The AWS Diagnostic Development Initiative has accelerated projects that are having an immediate impact on COVID-19 detection and changing what's possible with medical diagnostics. These projects are not only helping the medical community rapidly respond to COVID-19, but also supporting important work for many other infectious diseases. Here are just a few of the projects funded by the AWS Diagnostic Development Initiative:

Stanford University School of Medicine develops smartwatch-based 'alarm system' for diagnostics

Researchers at the Stanford University School of Medicine's Healthcare Innovation Labhave developed a smartwatch app designed to correctly flag signs of a person's immune system fighting a potential COVID-19 infection. The app is powered by an algorithm that detects changes in an individual's resting heart rate and step count. Early results are promising, and a pilot trial successfully alerted newly infected individuals as early as 10 days before they became aware of any symptoms. The app has entered the next phase of study, and the Stanford team is recruiting participants with the goal of reaching 10 million participants to increase its ability to detect signs of COVID-19 in real time. This smartwatch-based early detection system was built on AWS with the support of the AWS Professional Services team, who collaborated with the researchers to help the study scale its data processing pipeline.

Image of Stanford University's COVID-19 Wearables Study app called MyPHD
Image of Stanford University's COVID-19 Wearables Study app called MyPHD

'We're hopeful that ongoing screening using wearable devices can provide scalable diagnostics solutions to overcome current testing barriers, and that expanding data access to a broader range of researchers will contribute to new discoveries that improve human health,' said Michael Snyder, Ph.D., professor and chair of genetics for Stanford University's School of Medicine. 'We look forward to continue pushing the boundaries of what is possible with the cloud.'

Michael Snyder, PhD, professor and chair of genetics for Stanford University's School of Medicine
Image of Stanford University's COVID-19 Wearables Study app called MyPHD
Michael Snyder, PhD, professor and chair of genetics for Stanford University's School of Medicine
Illumina accelerates the identification of viral mutations through next-gen sequencing

Genomics is playing a fundamental role during the COVID-19 pandemic, and Illumina is driving the implementation of genomics through rapid innovation. The viral genome of SARS-CoV-2 was first sequenced on Illumina technology in China and made public on January 11, 2020. As part of a comprehensive strategy to bring rapid solutions to its customers and the global scientific community in the face of the pandemic, Illumina released itsSARS-CoV-2 Data Toolkitin April 2020. The toolkit includes a number of apps built-for-purpose to analyze COVID-19 samples on its BaseSpace™ Sequence Hub, which runs on Amazon Elastic Compute Cloud (EC2). The focused analysis pipelines in the toolkit were made available to researchers at no cost for six months in 2020. As a result, Illumina has helped over 800 users process viral sequencing samples across its different apps. As genomic surveillance became more prominent toward the end of 2020, use of the toolkit's DRAGEN COVID Lineage app-used to identify mutations in the viral genome-has escalated rapidly as health experts track for known and emerging variants that could inform public health decisions.

'Currently, many countries are reaching a point whereby public health agencies need to maintain an accurate catalog of the variants in their region, detect emerging strains, and assess any individual strain's potential to impact vaccine effectiveness,' said Phil Febbo, MD, chief medical officer of Illumina. 'Our partners and customers rely on Illumina's high-quality sequencing and data analytics to ensure accurate viral genomes and strain typing-which require immense computing power and processing. We value the innovative and scalable cloud-based infrastructure offered by AWS which enable critical worldwide cooperation-an essential factor in seeing the end to this pandemic.'

Helix ramps up high-sensitivity COVID-19 testing across the U.S.

Helix, a genomics startup that has built its entire software platform on AWS, is rapidly expanding access to high-sensitivity molecular COVID-19 testing with next-day turnaround time for health systems, employers, governments, and other organizations across the U.S. The Helix® COVID-19 Testhas received Emergency Use Authorization from the U.S. Food and Drug Administration (FDA), and the company is scaling to process up to 100,000 COVID-19 tests per day in the U.S., making it one of the nation's largest COVID-19 testing laboratories. Helix provides an end-to-end, highly scalable solution to detect active COVID-19 infections by enabling easy self-collection of samples with lower nasal swabs, and a choice of unsupervised or supervised on-site sample collection.

'Working with AWS has enabled us to not only stand up a COVID-19 solution in short order, but also allowed Helix to scale quickly to meet a surge of testing demand this past winter. The impact of this is huge. As the pandemic worsened, we were able to build on a foundation of AWS technology that enabled us to help thousands of communities-millions of lives-all across the United States,' said Jim Chou, vice president of engineering at Helix.

Centro Diagnostico Italiano and Bracco Imaging create open-source imaging archive project

A consortium of healthcare and research organizations led by Centro Diagnostico Italiano and Bracco Imaging collaborated to create the AIforCOVID Imaging Archive, a repository with almost 1,000 chest X-rays and anonymized clinical data of COVID-19 patients. Images and clinical data were analyzedusing three machine learning approaches developed by the research organizations and performed on AWS. Based on these analyses, the consortium developed a model that is able to predict the clinical outcome of COVID-19 patients from chest X-ray images and clinical data. All data collected by the AIforCOVID network is available for download to members of the international scientific community from the project's website.

'Radiological imaging is playing a crucial role in COVID-19 patient management for diagnosis and treatment selection. Thanks to the power of machine learning delivered by AWS's technology and professional support, we have been able to quickly make sense of the vast volume of data generated by diagnostic imaging and clinical analyses,' said Sergio Papa, director of diagnostic imaging and stereotactic radiosurgery, Centro Diagnostico Italiano. 'We are working to deliver a practical resource that hospitals and organizations around the world can apply to increase their understanding of the disease, facilitate their own diagnostic efforts, and improve patient treatment.'

'Working with the Centro Diagnostico Italiano and AWS, we have begun exploring the potential of applying artificial intelligence to clinical data, and we realized that we are just starting to grasp the extent of this revolution,' said Fabio Tedoldi, research and development director, Bracco Global Business Unit Imaging. 'Healthcare is moving quickly toward new ways of integrating and interconnecting data with clinical practice and patient management.'

Related Tags

Disclaimer

Amazon.com Inc. published this content on 12 April 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 April 2021 12:36:04 UTC.


© Publicnow 2021
All news about AMAZON.COM, INC.
05/07AMAZON COM  : Partnering With Tile, Level For New Sidewalk Features
MT
05/07INSIDER TRENDS : Insider 90-Day Selling Trend Extended at Amazon.com
MT
05/07INSIDER TRENDS : Amazon.com Insider Extends 90-Day Selling Trend
MT
05/07INSIDER TRENDS : Insider Adds to Selling Trend at Amazon.com
MT
05/07AMAZON COM  : Announces First Robotics Fulfillment Center in Louisiana
BU
05/07AMAZON COM  : union tussle over identifying witnesses as U.S. labor board starts..
RE
05/07AMAZON COM  : ‘I see EVERYTHING!' Getting real with Amazon moms on Mother'..
PU
05/07AMAZON COM  : Echo, Tile, and Level devices join Amazon Sidewalk
PU
05/07AMAZON COM  : pauses annual Prime Day sale in India due to COVID-19
RE
05/07AMAZON COM  : Canada's Lion Electric says it will build new plant in Illinois, c..
RE
More news
Financials (USD)
Sales 2021 490 B - -
Net income 2021 28 466 M - -
Net cash 2021 82 973 M - -
P/E ratio 2021 59,9x
Yield 2021 -
Capitalization 1 660 B 1 660 B -
EV / Sales 2021 3,22x
EV / Sales 2022 2,68x
Nbr of Employees 1 298 000
Free-Float 81,8%
Chart AMAZON.COM, INC.
Duration : Period :
Amazon.com, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMAZON.COM, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 53
Average target price 4 228,80 $
Last Close Price 3 291,61 $
Spread / Highest target 67,1%
Spread / Average Target 28,5%
Spread / Lowest Target 13,9%
EPS Revisions
Managers and Directors
NameTitle
Jeffrey P. Bezos Chairman, President & Chief Executive Officer
Brian T. Olsavsky Chief Financial Officer & Senior Vice President
Patricia Q. Stonesifer Independent Director
Thomas O. Ryder Independent Director
Jonathan Jake Rubinstein Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMAZON.COM, INC.1.52%1 660 037
JD.COM, INC.-14.10%116 583
WAYFAIR INC.35.29%31 832
ETSY, INC.-6.97%21 037
ALLEGRO.EU SA-35.23%14 980
MONOTARO CO., LTD.-3.01%11 652